|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Ascending Oral Doses of SUL-238 in Healthy Subjects
The goal of this randomized, double-blind, placebo-controlled, single-center study is to evaluate the safety, tolerability, pharmacokinetics of single and multiple oral doses of SUL-238 in healthy subjects (aged ≥40 years).
A Multicenter Randomized Double-blind Placebo-controlled Parallel Group Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 Cream Used in the Treatment of Mild to Moderate Plaque Psoriasis
This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerability of GN-037 versus clobetasol 17-propionate and placebo in patients diagnosed with mild to moderate plaque psoriasis at least 6 months ago
100 项与 Gen Ilaç ve Saglik Ürünleri Sanayi ve Ticaret AS 相关的临床结果
0 项与 Gen Ilaç ve Saglik Ürünleri Sanayi ve Ticaret AS 相关的专利(医药)
100 项与 Gen Ilaç ve Saglik Ürünleri Sanayi ve Ticaret AS 相关的药物交易
100 项与 Gen Ilaç ve Saglik Ürünleri Sanayi ve Ticaret AS 相关的转化医学